DexCom still stands out to investors
Recent investment analysis highlighted DexCom’s stronger profitability and market valuation relative to some rivals, keeping the CGM maker in focus for investors and product watchers. That financial resilience matters for R&D cadence and pricing pressures in the CGM market. (themarketsdaily.com)
Dexcom reported fourth-quarter revenue of $1.26 billion and GAAP operating income of $323.0 million (25.6% of revenue) for the quarter ended Dec. 31, 2025. (investors.dexcom.com) For fiscal 2026 the company reiterated revenue guidance of $5.16–$5.25 billion and non‑GAAP gross‑profit and operating‑margin targets of roughly 63–64% and 22–23%, respectively. (investors.dexcom.com) Dexcom exited 2025 with roughly $2.0 billion in cash and cash equivalents, reported more than $1 billion in free cash flow for the year, repurchased about $300 million of stock and settled $1.2 billion of expiring convertible notes in cash. (biospace.com) The company’s market capitalization sits near $26 billion as of mid‑March 2026, placing it well above smaller diabetes‑device peers such as Insulet (about $16–17 billion) but far below diversified rivals like Abbott, whose market cap is roughly $188–191 billion. (stockanalysis.com) Dexcom’s stated operating margins and recent quarterly profitability outpace several diabetes incumbents — Medtronic’s FY‑2025 GAAP operating margin ran around 17.8% while Insulet’s operating income was near 16.7% in recent quarters — underscoring why analysts point to Dexcom’s relative margin strength. (investors.dexcom.com) Management continues to invest in product cadence — R&D expense rose to about $599 million in 2025 while the company showcased new G7 registry outcomes and the US retail rollout of a G7 15‑day product at ATTD 2026 — a pipeline cadence funded in part by the company’s cash flow and balance‑sheet actions. (macrotrends.net) Competitive and payer dynamics remain a counterweight: Abbott’s FreeStyle Libre family reached roughly $8 billion in sales in 2025, insurers and Medicare plans are moving many CGM fills to pharmacy benefits and listing preferred devices, and that scale and benefit‑channel shift increases downward price pressure across the market. (panabee.com) Analyst sentiment has followed, with firms like Mizuho raising Dexcom’s target to $90 and BTIG maintaining an $85 price objective after the company’s results and G7 data presentations. (marketbeat.com)
